Get the Stockscreener App
24.69
1.98%
-0.50
After Hours:
24.69
Indivior Plc stock is traded at $24.69, with a volume of 1.09M.
It is down -1.98% in the last 24 hours and up +8.43% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$25.19
Open:
$25.46
24h Volume:
1.09M
Relative Volume:
0.43
Market Cap:
$3.06B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
2,469.00
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
+2.24%
1M Performance:
+8.43%
6M Performance:
+172.52%
1Y Performance:
+203.32%
1-Day Range:
$24.53
$25.49
1-Week Range:
$22.95
$25.49
52-Week Range:
$7.62
$25.49
Indivior Plc Stock (INDV) Company Profile
Name
Indivior Plc
Sector
Phone
804-379-1090
Address
234 BATH ROAD, SLOUGH, BERKSHIRE
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
24.69 | 3.06B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
143.26 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.88 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.20 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.63 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
432.69 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Plc Stock (INDV) Latest News
Indivior Q2 2025 presentation: SUBLOCADE growth drives raised guidance By Investing.com - Investing.com Nigeria
Indivior stock hits 52-week high at 25.1 USD By Investing.com - Investing.com Nigeria
Indivior stock hits 52-week high at 25.1 USD - Investing.com
Using AI based signals to follow Indivior PLCPortfolio Risk Report & Real-Time Stock Entry Alerts - newser.com
How Indivior PLC stock trades during market volatilityWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
Clinical Evidence Supports Rapid SUBLOCADE Induction As A Strategy To Improve Retention In Opioid Use Disorder Treatment - TradingView
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment (2025-10-15) - Seeking Alpha
Can Indivior PLC stock reach $100 price targetEarnings Growth Report & Free Community Consensus Stock Picks - newser.com
News impact scoring models applied to Indivior PLCWeekly Loss Report & Daily Chart Pattern Signal Reports - newser.com
Using Python tools to backtest Indivior PLC strategiesJuly 2025 Patterns & Intraday High Probability Setup Alerts - newser.com
Is Indivior PLC stock reversal real or fake2025 Market WrapUp & Safe Capital Growth Tips - newser.com
Earnings call transcript: Indivior’s Q2 2025 revenue rises, guidance boosted - Investing.com
Earnings call transcript: Indivior’s Q2 2025 revenue rises, guidance boosted By Investing.com - Investing.com Canada
Will Indivior PLC stock deliver long term returnsJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Substance Abuse Treatment Market to Witness Remarkable Growth With Indivior PLC, Pfizer, Inc. - openPR.com
Chart based exit strategy for Indivior PLCEarnings Trend Report & Scalable Portfolio Growth Methods - newser.com
How Indivior PLC stock performs in rising dollar environment2025 EndofYear Setup & Weekly Market Pulse Alerts - newser.com
Indivior targets $1.5B peak revenue for Sublocade amid 2025 transition plans - MSN
Will Indivior PLC stock rally after Fed decisionsMarket Weekly Review & Weekly Momentum Picks - newser.com
Will Indivior PLC benefit from macro trendsJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
Strategies to average down on Indivior PLCJuly 2025 Review & Target Return Focused Picks - newser.com
Indivior PLC stock outlook for YEARTrade Exit Summary & Entry Point Confirmation Alerts - newser.com
Will Indivior PLC outperform the marketJuly 2025 Action & Expert Curated Trade Setups - newser.com
What indicators show strength in Indivior PLCTrade Analysis Report & Daily Volume Surge Signals - newser.com
U.S. Suboxone Market Set to See Booming Growth 2025-2032 Driven by Key Players like Indivior, Teva, and Alcami - openPR.com
Substance Abuse Treatment Market Size, Growth Analysis 2031 - openPR.com
What the charts say about Indivior PLC today2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Indivior Launches Action Agenda for Business Enhancement - MSN
What analysts say about Indivior PLC stockHigh Dividend Yield Stocks & Big Profit Small Budget - earlytimes.in
Automated trading signals detected on Indivior PLC2025 Short Interest & Daily Volume Surge Trade Alerts - newser.com
Full technical analysis of Indivior PLC stockJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
Why Indivior PLC stock remains resilient2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
Should you wait for a breakout in Indivior PLC2025 Trading Recap & Stock Portfolio Risk Control - newser.com
Can momentum traders help lift Indivior PLCMarket Risk Report & Fast Moving Stock Watchlists - newser.com
Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M - MSN
US AG stops misleading marketing of unauthorized opioid overdose drug by Indivior - The Pharma Letter
Indivior plans U.S. domicile shift from U.K. to enhance Nasdaq presence - Investing.com Nigeria
UK's Indivior to re-domicile to US after listing move - Global Banking | Finance | Review
Opvee, High-Profile Overdose Antidote No One Used, Discontinues Marketing - Filter
UK’s Indivior to re-domicile to US after listing move - 104.1 WIKY
Indivior proposes new corporate structure to achieve U.S. domiciliation - MarketScreener
Indivior Plc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
5.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):